Human Genome Sciences (HGSI) CEO Buys 100K Shares
More News related to HGSI
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
- JPMorgan Boosts Target on Human Genome (HGSI) to $35
- Goldman Sachs Lifts Tgt on Human Genome Sciences (HGSI) to $30, Sees As Acquisition Candidate
- Human Genome (HGSI) volatility low at 73 after announcing positive data
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
Human Genome Sciences Inc. (Nasdaq: HGSI)President and CEO, Thomas Watkins, purchased 100,000 shares on 11/12 at a price of $2.02, bringing his stake to 170,274 shares.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the Unites States.
Related Categories
Insider TradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
